0H7R.LAbeona Therapeutics Inc.

Über

Abeona Therapeutics Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of gene and cell therapies to combat critical, uncommon genetic illnesses. Their foremost developmental asset is EB-101, a personalized gene-corrected cell therapy that has progressed to Phase III clinical trials for the treatment of recessive dystrophic epidermolysis bullosa. The company's pipeline also encompasses several other programs: ABO-102, an adeno-associated virus (AAV)-based gene therapy designed for Sanfilippo syndrome type A; ABO-201, aimed at CLN3 disease; ABO-401, targeting cystic fibrosis; and ABO-50X, intended for genetic eye disorders. Additionally, Abeona actively advances AAV-based gene therapies through its proprietary AIM vector platform. Incorporated in 1974, the firm was initially named PlasmaTech Biopharmaceuticals, Inc. before officially adopting the name Abeona Therapeutics Inc. in June 2015. The company's corporate base is situated in New York, New York.

www.abeonatherapeutics.com

Kennzahlen

Marktkapitalisierung

297.50M

EPS

1.34

Dividendenrendite

0.00%

Beta

1.35

KBV

1.78

EK-Rendite

44.7%

Sektor

Healthcare

Branche

Biotechnology

CEO

Vishwas Seshadri

Mitarbeiter

136

IPO-Datum

2018-01-29

Land

US